https://www.thelancet.com/pdfs/journals/lanpsy/PIIS2215-0366(16)30065-7.pdf

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Fungus associates of ectotrophic mycorrhizae

Simple indole alkaloids and those with a nonrearranged monoterpenoid unit

Psilocybin and related hallucinogenic compounds are increasingly used in human research. However, due to limited information about potential subjective side effects, the controlled medical use of these compounds has remained controversial. We therefore analysed acute, short- and long-term subjective effects of psilocybin in healthy humans by pooling raw data from eight double-blind placebo-controlled experimental studies conducted between 1999 and 2008. The analysis included 110 healthy subjects who had received 1-4 oral doses of psilocybin (45-315 µg/kg body weight). Although psilocybin dose-dependently induced profound changes in mood, perception, thought and self-experience, most subjects described the experience as pleasurable, enriching and non-threatening. Acute adverse drug reactions, characterized by strong dysphoria and/or anxiety/panic, occurred only in the two highest dose conditions in a relatively small proportion of subjects. All acute adverse drug reactions were successfully managed by providing interpersonal support and did not need psychopharmacological intervention. Follow-up questionnaires indicated no subsequent drug abuse, persisting perception disorders, prolonged psychosis or other long-term impairment of functioning in any of our subjects. The results suggest that the administration of moderate doses of psilocybin to healthy, high-functioning and well-prepared subjects in the context of a carefully monitored research environment is associated with an acceptable level of risk.

http://journals.sagepub.com/doi/pdf/10.1177/0269881110382466

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.

https://spiral.imperial.ac.uk/bitstream/10044/1/48247/2/Circumspectives_PDF.pdf

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future

The active principle ofPsilocybe mexicana Heim, a mexican mushroom with hallucinogenic properties, has been isolated in crystalline form. The compound has been given the namePsilocybin; it possesses indole characteristics and contains phosphorus. A second substance, closely related toPsilocybin but found only in traces, has been calledPsilocin.

Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim

The psychotropically active principles of the Mexican hallucinogenic fungus Psilocybe maxicana HEIM have been isolated and obtained in crystalline form. The two new substances, which have been called psilocybin and psilocin, are present in the fruit bodies, the artificially cultivated mycelium and in the sclerotia. The dried mushroom contains 0.2 to 0.4 per cent psilocybin. Psilocin is present, at the most, in trace amounts only.

Roger Heim

Papers

Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen RauschpilzPsilocybe mexicana Heim

Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen

Termites et Champignons: Les champignons termitophiles d'Afrique Noire et d'Asie meridionale

Le genre Inocybe

Les Champignons Toxiques et Hallucinogenes